신경 퇴행성 질환 시장 : 시장 인사이트, 경쟁 구도, 시장 예측(2034년)

Neurodegenerative Disease Market Summary

• The global neurodegenerative disease market is expected to increase from USD 53,942.79 million in 2025 to USD 93,173.35 million by 2034, reflecting strong and sustained growth.
• The global neurodegenerative disease market is growing at a CAGR of 6.32% during the forecast period from 2026 to 2034.
• The Neurodegenerative Disease Treatment market is experiencing significant growth due to the rising global prevalence of disorders such as Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis, which is increasing the demand for effective therapeutic solutions. At the same time, advancements in disease-modifying therapies are transforming treatment approaches by targeting the underlying causes of disease progression rather than only managing symptoms. The expanding pipeline of RNA-based therapies, gene therapies, and cell therapies is further creating new opportunities for treating both common and rare neurodegenerative conditions, attracting substantial industry interest and investment. Additionally, increasing funding for neuroscience research and drug development from pharmaceutical companies, biotechnology firms, governments, and research institutions is accelerating innovation, clinical trial activity, and the commercialization of novel treatments. Collectively, these factors are driving the growth and evolution of the Neurodegenerative Disease Treatment market worldwide.
• The leading companies operating in the neurodegenerative disease market include Eisai Co., Ltd., AbbVie Inc., Johnson & Johnson, Novartis AG, Biogen Inc., Eli Lilly and Company, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc (GSK plc), H. Lundbeck A/S, Supernus Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences, Inc., PTC Therapeutics, Inc., and others.
• North America is expected to dominate the Neurodegenerative Disease Treatment market due to the high prevalence of neurodegenerative disorders, a rapidly aging population, and strong healthcare infrastructure across the region. The presence of leading pharmaceutical and biotechnology companies, substantial investments in neuroscience research, and favorable regulatory support for innovative therapies are accelerating the development and adoption of advanced treatments. Additionally, increasing approvals of disease-modifying therapies, widespread access to specialized neurological care, and strong reimbursement frameworks further contribute to the region's market leadership.
• In the indication segment of the neurodegenerative disease market, the Alzheimer's Disease category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Neurodegenerative Disease Market

• Rising global prevalence of neurodegenerative disorders: The increasing incidence and prevalence of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis are significantly driving demand for effective therapeutic interventions. Improved diagnosis rates and growing disease awareness are further expanding the patient pool requiring long-term treatment.
• Advancements in disease-modifying therapies: The development and commercialization of innovative therapies, including monoclonal antibodies, antisense oligonucleotides (ASOs), gene therapies, and other biologics, are transforming the treatment landscape. Recent approvals of disease-modifying treatments for Alzheimer's disease and rare neurological disorders have increased investment and accelerated market growth.
• Increasing investment in neuroscience research and drug development: Pharmaceutical and biotechnology companies are significantly increasing research and development spending to address the substantial unmet medical needs associated with neurodegenerative diseases. Growing funding from governments, academic institutions, and private investors is supporting the discovery of novel therapeutic targets and next-generation treatment platforms.
• Expanding pipeline of RNA-Based, gene, and cell therapies: The emergence of advanced therapeutic modalities such as antisense oligonucleotides, RNA-splicing therapies, gene therapies, and regenerative cell therapies is creating new opportunities for treating previously untreatable neurodegenerative conditions. These innovations are expected to drive long-term market expansion.

Neurodegenerative Disease Market Report Segmentation

This neurodegenerative disease market report offers a comprehensive overview of the global neurodegenerative disease market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and Others), Molecule Type (Small Molecule and Biologics), Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, MAO-B Inhibitor, Dopamine Agonists, and Others), Route of Administration (Oral, Subcutaneous, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing neurodegenerative disease market.

Neurodegenerative diseases are a group of progressive disorders characterized by the gradual loss of structure and function of neurons in the brain and nervous system. This neuronal damage leads to worsening cognitive, motor, and functional abilities over time. Common neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. These conditions are typically chronic, irreversible, and currently have no definitive cure, although treatments are available to manage symptoms and slow disease progression.

The Neurodegenerative Disease Treatment market is witnessing strong and sustained growth, primarily driven by the increasing global burden of disorders such as Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis, which is significantly expanding the patient population in need of long-term therapeutic care. This rising prevalence is further intensified by aging demographics worldwide, leading to a higher incidence of age-associated neurological decline and creating continuous demand for both symptomatic and disease-modifying treatments.

At the same time, advancements in disease-modifying therapies are reshaping the treatment landscape by shifting the focus from symptom management to targeting the underlying pathological mechanisms, thereby improving clinical outcomes and slowing disease progression. In addition, the rapid expansion of the pipeline for RNA-based therapies, gene therapies, and cell-based therapies is opening new avenues for addressing previously untreatable or poorly managed conditions, attracting strong interest from pharmaceutical and biotechnology companies. Furthermore, increasing investments in neuroscience research and drug development by industry players, academic institutions, and government bodies are accelerating innovation, supporting large-scale clinical trials, and facilitating faster commercialization of novel therapeutics. Collectively, these factors are transforming the Neurodegenerative Disease Treatment market into a highly innovative and rapidly evolving therapeutic area with significant long-term growth potential.

What are the latest neurodegenerative disease market dynamics and trends?

The rising prevalence of neurodegenerative disease is significantly increasing the demand for neurodegenerative therapies, thereby accelerating the neurodegenerative disease markets worldwide.

Dementia: According to the data provided by the World Health Organization (2025), approximately 57 million people had dementia worldwide. Dementia, particularly Alzheimer's disease-related dementia, is a major driver of the neurodegenerative disease treatment market due to its rapidly increasing global prevalence among the aging population. The growing number of patients experiencing cognitive decline, memory loss, and functional impairment is significantly boosting demand for both symptomatic and disease-modifying therapies. Recent advancements in amyloid-targeting monoclonal antibodies and early diagnostic tools are further expanding treatment adoption and fueling market growth.

Parkinson's Disease: According to the data provided by the Parkinson's Foundation (2025), more than 10 million people worldwide were estimated to be living with PD. Parkinson's disease is contributing substantially to market expansion as its incidence continues to rise worldwide, especially in elderly populations. The increasing burden of motor and non-motor symptoms is driving demand for dopaminergic therapies, MAO-B inhibitors, and advanced treatment options such as continuous drug delivery systems. Additionally, ongoing research into neuroprotective agents and disease-modifying therapies is strengthening the pipeline, encouraging higher investment and long-term market growth.

Multiple Sclerosis: According to the data provided by the World Health Organization (2023), it was estimated that over 1.8 million people have MS worldwide. Multiple Sclerosis is a key growth driver in the neurodegenerative disease treatment market due to the expanding use of advanced immunomodulatory and biologic therapies. The increasing prevalence of relapsing-remitting MS and rising diagnosis rates in both developed and emerging regions are fueling demand for disease-modifying treatments. The strong presence of monoclonal antibodies, S1P receptor modulators, and oral small-molecule therapies is further enhancing treatment options and accelerating market expansion.

Additionally, the neurodegenerative disease treatment market is being significantly boosted by advancements in disease-modifying therapies, which are shifting treatment strategies from symptomatic relief to slowing or altering disease progression. This transformation is evident in recent FDA approvals, such as Leqembi in January 2023 in the U.S., which targets amyloid-beta in Alzheimer's disease and represents a major milestone in disease-modifying approaches. Similarly, the expanding pipeline of RNA-based, gene, and cell therapies is opening new possibilities for previously untreatable conditions, with FDA approvals like Qalsody in April 2023, for SOD1-ALS, highlighting the rapid progress in advanced therapeutic modalities. In addition, increasing investment in neuroscience research and drug development by pharmaceutical and biotechnology companies is accelerating clinical trial activity and innovation, enabling faster translation of novel mechanisms into approved therapies, such as Kisunla, which received U.S. FDA approval in July 2024 for Alzheimer's disease.

Collectively, these developments are strengthening the therapeutic pipeline, improving patient outcomes, and driving sustained growth in the neurodegenerative disease treatment market globally.

However, the neurodegenerative disease treatment market is significantly constrained by a high failure rate in clinical trials and the physiological barrier posed by the blood-brain barrier (BBB). Many drug candidates fail during late-stage development due to inadequate efficacy, safety concerns, or inability to demonstrate meaningful clinical improvement in complex central nervous system disorders. At the same time, the BBB restricts the penetration of large molecules and many small drugs into the brain, limiting therapeutic effectiveness and reducing the success of biologics and disease-modifying therapies. Together, these challenges make drug development in neurodegenerative diseases highly complex, time-consuming, and costly, thereby slowing the introduction of effective new treatments to the market.

Neurodegenerative Disease Market Segment Analysis

Neurodegenerative Disease Market by Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and Others), Molecule Type (Small Molecule and Biologics), Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, MAO-B Inhibitor, Dopamine Agonists, and Others), Route of Administration (Oral, Subcutaneous, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Neurodegenerative Disease Market Regional Analysis

North America Neurodegenerative Disease Market Trends

North America is expected to account for the highest proportion of 42% of the neurodegenerative disease market in 2025, out of all regions. North America is significantly boosting the neurodegenerative disease treatment market due to a strong combination of advanced healthcare infrastructure, high disease prevalence, and rapid adoption of innovative therapies. The region, particularly the United States, has been at the forefront of advancements in disease-modifying therapies, with landmark approvals such as Leqembi receiving U.S. FDA approval in January 2023 for early Alzheimer's disease, marking a major shift from symptomatic treatment to disease-targeting interventions. This momentum continued with the approval of Kisunla in 2024, further strengthening amyloid-targeting treatment options and expanding clinical confidence in modifying disease progression.

Additionally, the increasing cases of neurodegenerative disorders across the region are further boosting the demand for neurodegenerative disease therapies. According to the data provided by the Parkinson's Foundation (2025), nearly 90,000 people were diagnosed with Parkinson's disease in the U.S. each year.

At the same time, North America is leading the expanding pipeline of RNA-based, gene, and cell therapies, supported by strong biotech ecosystems in hubs such as Boston and San Francisco, where companies and research institutions are actively developing antisense oligonucleotides, gene replacement therapies, and regenerative cell-based treatments for conditions like ALS and spinal muscular atrophy. Additionally, increasing investment in neuroscience research and drug development from major pharmaceutical companies such as Biogen, Eli Lilly and Company, and Roche is accelerating clinical trials, biomarker discovery, and precision medicine approaches. For example, in 2023, Biogen and Eisai expanded their clinical and commercialization investment in Alzheimer's disease programs following the U.S. FDA approval of Leqembi, significantly increasing R&D allocation toward disease-modifying therapies. Similarly, in 2024, Eli Lilly and Company strengthened its neuroscience pipeline investment after the approval of Kisunla, further driving large-scale clinical trials and biomarker research initiatives. Government support from agencies like the U.S. NIH, along with strong venture capital funding for neurotechnology and biotech startups, is further enhancing innovation in the region.

Collectively, these factors are making North America the dominant hub for neurodegenerative disease research, innovation, and commercialization, thereby driving substantial growth in the global market.

Europe Neurodegenerative Disease Market Trend

The European neurodegenerative disease treatment market is witnessing strong and sustained growth due to a rising aging population, increasing prevalence of disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, and a highly structured and well-funded healthcare system across the region. Europe has also emerged as a key hub for clinical research and early adoption of innovative therapies, supported by strong regulatory frameworks from the European Medicines Agency (EMA) that facilitate accelerated approvals for high-need neurological treatments. Recent developments have further strengthened market growth, including the continued rollout and adoption of disease-modifying Alzheimer's therapies such as Leqembi following its EU regulatory approval in April 2025, expanding access across major European markets like Germany and the UK. In addition, increasing investment in neuroscience R&D by leading pharmaceutical companies such as Roche and Novartis has accelerated clinical trials focused on multiple sclerosis, neurodegeneration biomarkers, and gene-based therapies in Europe. Europe has also seen growing participation in cross-border research initiatives and EU-funded programs such as Horizon Europe, which continue to support innovation in RNA-based and cell-based therapies for rare neurodegenerative disorders.

Collectively, these advancements in regulatory support, clinical innovation, and public-private investment are driving the steady expansion of the neurodegenerative disease treatment market across Europe.

Asia-Pacific Neurodegenerative Disease Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the neurodegenerative disease treatment market due to its rapidly aging population, increasing burden of neurological disorders, and improving access to advanced healthcare services. Countries such as Japan, China, India, and South Korea are witnessing a sharp rise in cases of Alzheimer's disease, Parkinson's disease, and other dementia-related conditions, which is significantly expanding the patient pool and driving demand for both symptomatic and disease-modifying therapies. The region is also experiencing rapid improvements in diagnostic capabilities, hospital infrastructure, and neurology care networks, enabling earlier detection and treatment initiation. In recent years, APAC has seen growing participation in global clinical trials and increasing adoption of advanced therapies, including biologics and small-molecule treatments for neurodegenerative disorders. For instance, several multinational companies, including Eli Lilly and Company and Roche, expanded their Alzheimer's and Parkinson's disease clinical programs across Japan and China to accelerate patient recruitment and regional approvals. Additionally, increasing healthcare investments by governments, particularly in China's national neuroscience initiatives and Japan's dementia care strategies, are strengthening research and treatment accessibility. Collectively, these factors are positioning APAC as one of the fastest-growing regions in the global neurodegenerative disease treatment market.

Who are the major players in the neurodegenerative disease market?

The following are the leading companies in the neurodegenerative disease market. These companies collectively hold the largest market share and dictate industry trends.

• Eisai Co., Ltd.
• AbbVie Inc.
• Johnson & Johnson
• Novartis AG
• Biogen Inc.
• Eli Lilly and Company
• Amneal Pharmaceuticals, Inc.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc (GSK plc)
• H. Lundbeck A/S
• Supernus Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Neurocrine Biosciences, Inc.
• PTC Therapeutics, Inc.
• Others

How is the competitive landscape shaping the Neurodegenerative Disease market?

The competitive landscape of the neurodegenerative disease treatment market is becoming increasingly dynamic and innovation-driven, shaped by strong competition among global pharmaceutical and biotechnology companies focused on both symptomatic and disease-modifying therapies. Established players such as Biogen, Eli Lilly and Company, Roche, and Novartis are leading the market through extensive investments in Alzheimer's disease, multiple sclerosis, and Parkinson's disease pipelines, particularly in monoclonal antibodies, RNA-based therapies, and advanced biologics. Recent landmark approvals such as Leqembi (2023) and Kisunla (2024) have intensified competition in the Alzheimer's space, pushing companies to accelerate development of next-generation amyloid- and tau-targeting therapies. At the same time, emerging biotech firms and specialized neuroscience companies are increasingly entering the market with novel approaches such as antisense oligonucleotides, gene therapies, and cell-based treatments, further intensifying innovation pressure. Strategic collaborations, licensing agreements, and mergers and acquisitions are also reshaping the competitive environment, as large pharmaceutical companies seek to strengthen their neuroscience portfolios and expand access to advanced technologies. Additionally, increasing focus on precision medicine and biomarker-driven clinical trials is enabling companies to differentiate their pipelines and improve success rates. Collectively, these factors are creating a highly competitive and rapidly evolving landscape that is accelerating innovation and expanding treatment options in the neurodegenerative disease market.

Recent Developmental Activities in the Neurodegenerative Disease Market

• In April 2025, LEQEMBI received the European Commission (EC) approval. It is the first disease-modifying therapy authorized in Europe to slow cognitive decline in the early stages of Alzheimer's disease.

Neurodegenerative Disease Market Segmentation

• Neurodegenerative Disease by Disease Type Exposure
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis (MS)
• Amyotrophic Lateral Sclerosis (ALS)
• Others
• Neurodegenerative Disease by Molecule Type Exposure
• Small Molecules
• Biologics
• Neurodegenerative Disease by Drug Class Exposure
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• MAO-B Inhibitor
• Dopamine Agonists
• Others
• Neurodegenerative Disease Route of Administration Exposure
• Oral
• Subcutaneous
• Others
• Neurodegenerative Disease Distribution Channel Exposure
• Hospital Pharmacies
• Retail Pharmacies
• Others
• Neurodegenerative Disease Geography Exposure
• North America Neurodegenerative Disease Market
• United States Neurodegenerative Disease Market
• Canada Neurodegenerative Disease Market
• Mexico Neurodegenerative Disease Market
• Europe Neurodegenerative Disease Market
• United Kingdom Neurodegenerative Disease Market
• Germany Neurodegenerative Disease Market
• France Neurodegenerative Disease Market
• Italy Neurodegenerative Disease Market
• Spain Neurodegenerative Disease Market
• Rest of Europe Neurodegenerative Disease Market
• Asia-Pacific Neurodegenerative Disease Market
• China Neurodegenerative Disease Market
• Japan Neurodegenerative Disease Market
• India Neurodegenerative Disease Market
• Australia Neurodegenerative Disease Market
• South Korea Neurodegenerative Disease Market
• Rest of Asia-Pacific Neurodegenerative Disease Market
• Rest of the World Neurodegenerative Disease Market
• South America Neurodegenerative Disease Market
• Middle East Neurodegenerative Disease Market
• Africa Neurodegenerative Disease Market

Key takeaways from the neurodegenerative disease market report study

• Market size analysis for the current neurodegenerative disease market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the neurodegenerative disease market.
• Various opportunities available for the other competitors in the neurodegenerative disease market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current neurodegenerative disease market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the neurodegenerative disease market growth in the future.

Frequently Asked Questions for the Neurodegenerative Disease Market

1. What is the growth rate of the neurodegenerative disease market?

• The neurodegenerative disease market is estimated to grow at a CAGR of 6.32% during the forecast period from 2026 to 2034.

2. What is the market for neurodegenerative disease?

• The global neurodegenerative disease market is expected to increase from USD 53,942.79 million in 2025 to USD 93,173.35 million by 2034.

3. Which region has the highest share in the neurodegenerative disease market?

• North America is expected to dominate the Neurodegenerative Disease Treatment market due to the high prevalence of neurodegenerative disorders, a rapidly aging population, and strong healthcare infrastructure across the region. The presence of leading pharmaceutical and biotechnology companies, substantial investments in neuroscience research, and favorable regulatory support for innovative therapies are accelerating the development and adoption of advanced treatments. Additionally, increasing approvals of disease-modifying therapies, widespread access to specialized neurological care, and strong reimbursement frameworks further contribute to the region's market leadership.

4. What are the drivers for the neurodegenerative disease market?

• The Neurodegenerative Disease Treatment market is experiencing significant growth due to the rising global prevalence of disorders such as Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis, which is increasing the demand for effective therapeutic solutions. At the same time, advancements in disease-modifying therapies are transforming treatment approaches by targeting the underlying causes of disease progression rather than only managing symptoms. The expanding pipeline of RNA-based therapies, gene therapies, and cell therapies is further creating new opportunities for treating both common and rare neurodegenerative conditions, attracting substantial industry interest and investment. Additionally, increasing funding for neuroscience research and drug development from pharmaceutical companies, biotechnology firms, governments, and research institutions is accelerating innovation, clinical trial activity, and the commercialization of novel treatments. Collectively, these factors are driving the growth and evolution of the Neurodegenerative Disease Treatment market worldwide.

5. Who are the key players operating in the neurodegenerative disease market?

• Some of the key market players operating in the neurodegenerative disease market include Eisai Co., Ltd., AbbVie Inc., Johnson & Johnson, Novartis AG, Biogen Inc., Eli Lilly and Company, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc (GSK plc), H. Lundbeck A/S, Supernus Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences, Inc., PTC Therapeutics, Inc., and others.

Table of Contents

1. Neurodegenerative Disease Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Neurodegenerative Disease Market Executive Summary

• 2.1 Market at Glance

3. Neurodegenerative Disease Market Key Factors Analysis

• 3.1 Neurodegenerative Disease Market Drivers
  • 3.1.1 Rising global prevalence of neurodegenerative disorders
  • 3.1.2 Advancements in disease-modifying therapies
  • 3.1.3 Expanding pipeline of RNA-based, gene, and cell therapies
  • 3.1.4 Increasing investment in neuroscience research and drug development
• 3.2 Neurodegenerative Disease Market Restraints and Challenges
  • 3.2.1 High failure rate in clinical trials
  • 3.2.2 Blood-brain barrier (BBB) limitation
• 3.3 Neurodegenerative Disease Market Opportunity
  • 3.3.1 Growing scope for antisense oligonucleotides (ASOs), RNA interference, and RNA splicing technologies in conditions like ALS, SMA, and Huntington's disease

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

• 5.1 The United States
• 5.2 Europe
• 5.3 Japan
• 5.4 China

6. Neurodegenerative Disease Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Neurodegenerative Disease Market Assessment

• 7.1 By Disease Type
  • 7.1.1 Alzheimer's Disease
  • 7.1.2 Parkinson's Disease
  • 7.1.3 Multiple Sclerosis (MS)
  • 7.1.4 Amyotrophic Lateral Sclerosis (ALS)
  • 7.1.5 Others
• 7.2 By Molecule Type
  • 7.2.1 Small Molecule
  • 7.2.2 Biologics
• 7.3 By Drug Class
  • 7.3.1 Cholinesterase Inhibitors
  • 7.3.2 NMDA Receptor Antagonists
  • 7.3.3 MAO-B Inhibitor
  • 7.3.4 Dopamine Agonists
  • 7.3.5 Others
• 7.4 By Route of Administration
  • 7.4.1 Oral
  • 7.4.2 Subcutaneous
  • 7.4.3 Oral
• 7.5 By Distribution Channel
  • 7.5.1 Hospital Pharmacies
  • 7.5.2 Retail Pharmacies
  • 7.5.3 Others
• 7.6 By Geography
  • 7.6.1 North America
    • 7.6.1.1 United States Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.1.2 Canada Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.1.3 Mexico Neurodegenerative Disease Market Size in USD million (2023-2034)
  • 7.6.2 Europe
    • 7.6.2.1 France Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.2.2 Germany Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.2.3 United Kingdom Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.2.4 Italy Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.2.5 Spain Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.2.6 Rest of Europe Neurodegenerative Disease Market Size in USD million (2023-2034)
  • 7.6.3 Asia-Pacific
    • 7.6.3.1 China Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.3.2 Japan Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.3.3 India Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.3.4 Australia Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.3.5 South Korea Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.3.6 Rest of Asia-Pacific Neurodegenerative Disease Market Size in USD million (2023-2034)
  • 7.6.4 Rest of the World (RoW)
    • 7.6.4.1 Middle East Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.4.2 Africa Neurodegenerative Disease Market Size in USD million (2023-2034)
    • 7.6.4.3 South America Neurodegenerative Disease Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Neurodegenerative Disease Market Company and Product Profiles

• 10.1 Eisai Co., Ltd.
  • 10.1.1 Company Overview
  • 10.1.2 Company Snapshot
  • 10.1.3 Financial Overview
  • 10.1.4 Product Listing
  • 10.1.5 Entropy
• 10.2 AbbVie Inc.
  • 10.2.1 Company Overview
  • 10.2.2 Company Snapshot
  • 10.2.3 Financial Overview
  • 10.2.4 Product Listing
  • 10.2.5 Entropy
• 10.3 Johnson & Johnson
  • 10.3.1 Company Overview
  • 10.3.2 Company Snapshot
  • 10.3.3 Financial Overview
  • 10.3.4 Product Listing
  • 10.3.5 Entropy
• 10.4 Novartis AG
  • 10.4.1 Company Overview
  • 10.4.2 Company Snapshot
  • 10.4.3 Financial Overview
  • 10.4.4 Product Listing
  • 10.4.5 Entropy
• 10.5 Biogen Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Snapshot
  • 10.5.3 Financial Overview
  • 10.5.4 Product Listing
  • 10.5.5 Entropy
• 10.6 Eli Lilly and Company
  • 10.6.1 Company Overview
  • 10.6.2 Company Snapshot
  • 10.6.3 Financial Overview
  • 10.6.4 Product Listing
  • 10.6.5 Entropy
• 10.7 Amneal Pharmaceuticals, Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Snapshot
  • 10.7.3 Financial Overview
  • 10.7.4 Product Listing
  • 10.7.5 Entropy
• 10.8 Boehringer Ingelheim International GmbH
  • 10.8.1 Company Overview
  • 10.8.2 Company Snapshot
  • 10.8.3 Financial Overview
  • 10.8.4 Product Listing
  • 10.8.5 Entropy
• 10.9 GlaxoSmithKline plc (GSK plc)
  • 10.9.1 Company Overview
  • 10.9.2 Company Snapshot
  • 10.9.3 Financial Overview
  • 10.9.4 Product Listing
  • 10.9.5 Entropy
• 10.10 H. Lundbeck A/S
  • 10.10.1 Company Overview
  • 10.10.2 Company Snapshot
  • 10.10.3 Financial Overview
  • 10.10.4 Product Listing
  • 10.10.5 Entropy
• 10.11 Supernus Pharmaceuticals, Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Snapshot
  • 10.11.3 Financial Overview
  • 10.11.4 Product Listing
  • 10.11.5 Entropy
• 10.12 F. Hoffmann-La Roche Ltd.
  • 10.12.1 Company Overview
  • 10.12.2 Company Snapshot
  • 10.12.3 Financial Overview
  • 10.12.4 Product Listing
  • 10.12.5 Entropy
• 10.13 Sanofi S.A.
  • 10.13.1 Company Overview
  • 10.13.2 Company Snapshot
  • 10.13.3 Financial Overview
  • 10.13.4 Product Listing
  • 10.13.5 Entropy
• 10.14 Bristol-Myers Squibb Company
  • 10.14.1 Company Overview
  • 10.14.2 Company Snapshot
  • 10.14.3 Financial Overview
  • 10.14.4 Product Listing
  • 10.14.5 Entropy
• 10.15 Teva Pharmaceutical Industries Ltd.
  • 10.15.1 Company Overview
  • 10.15.2 Company Snapshot
  • 10.15.3 Financial Overview
  • 10.15.4 Product Listing
  • 10.15.5 Entropy
• 10.16 Mitsubishi Tanabe Pharma Corporation
  • 10.16.1 Company Overview
  • 10.16.2 Company Snapshot
  • 10.16.3 Financial Overview
  • 10.16.4 Product Listing
  • 10.16.5 Entropy
• 10.17 Neurocrine Biosciences, Inc.
  • 10.17.1 Company Overview
  • 10.17.2 Company Snapshot
  • 10.17.3 Financial Overview
  • 10.17.4 Product Listing
  • 10.17.5 Entropy
• 10.18 PTC Therapeutics, Inc.
  • 10.18.1 Company Overview
  • 10.18.2 Company Snapshot
  • 10.18.3 Financial Overview
  • 10.18.4 Product Listing
  • 10.18.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us